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A B S T R A C T
We describe a rare form of extrapulmonary tuberculosis and, to our knowledge, the 
first reported case of isolated splenic tuberculosis in association with adalimumab 
treatment. In the present case a borderline tuberculin skin test was attributed to the 
history of BCG vaccination and the more specific QuantiFERON-TB Gold test was 
negative, further perplexing the screening for latent tuberculosis infection in this oth-
erwise healthy individual before the initiation of anti-TNF therapy.
I N T R O D U C T I O N
The association of anti-tumor necrosis factor (anti-TNF) agents with new cases 
of active tuberculosis has been clearly demonstrated during the past decade. The 
incidence of active tuberculosis in infliximab-treated patients in Europe is estimated 
at 173:100,0001 and two European studies have shown that adalimumab carries a risk 
comparable to that of infliximab for the development of the infection.2,3 However, no 
standard guidelines have been established so far concerning the screening for latent 
tuberculosis infection (LTBI) of patients who are about to receive anti-TNF treatment.4 
The specificity of the tuberculin skin test (TST) is influenced by previous BCG vaccina-
tion and vaccination in adulthood may give persistent responses of more than 5 mm.4 
In addition, the more specific T cell interferon-γ (IFN-γ) release assay (IGRA), the 
QuantiFERON-TB Gold (QFT-G) test, may actually be inferior to the conventional 
TST in detecting LTBI.5 Some authors suggest that more than 50% of unvaccinated 
subjects with positive TST have negative QFT-G results.6,7 We herein present a case of 
isolated splenic tuberculosis, an extremely rare form of extrapulmonary tuberculosis, 
reported, to our knowledge, for the first time in association with adalimumab.
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TNF = tumor necrosis factor
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C A S e  R e p O R T
A 31-year-old male, human immunodeficiency virus 
(HIV)-negative patient, presented to us due to low grade fever 
in the afternoon hours accompanied by malaise and night 
sweats. His symptoms had begun 15 days earlier but his general 
condition was good. His past medical history was positive for 
cutaneous psoriasis which was successfully treated during the 
preceding 5 months with the monoclonal anti-TNF antibody 
adalimumab. He did not report any previous hospitalizations 
or any known contact with a case of tuberculosis. Prior to 
initiation of anti-TNF treatment he had undergone a TST with 
an induration of 8 mm and a negative QFT-G assay. There-
fore adalimumab had been initiated without antituberculous 
chemoprophylaxis. Physical examination was unremarkable 
except for a mildly enlarged spleen palpable on deep inspira-
tion. Complete blood count, erythrocyte sedimentation rate, 
C-reactive protein, biochemistry and urinalysis were all within 
normal limits and chest x-ray did not reveal any pathological 
findings.
Abdominal ultrasound, however, demonstrated multiple 
hypoechoic lesions of 1 to 1.7 cm within the spleen. A TST was 
performed on admission with a response of 22 mm. Computed 
tomography (CT) imaging of the abdomen showed multiple 
low-attenuation lesions of the spleen (Fig. 1), without involve-
ment of other organs, or enlarged lymph nodes or fluid collec-
tions. Computed tomography of the chest demonstrated nor-
mal lungs with no hilar or mediastinal lymphadenopathy. Blood 
and urine cultures were repeatedly negative and transthoracic 
echocardiogram revealed no valvular regurgitations or vegeta-
tions. Similarly, serologic evaluation for bartonella sp, coxiella 
burnetii, chlamydia sp and legionella sp was negative.
Anti-tuberculosis treatment was initiated with a 4-drug 
regimen with daily doses of 300 mg of isoniazid, 600 mg of 
rifampicin, 1500 mg of pyrazinamide and 1000 mg of etham-
butol. This was followed by rapid clinical improvement of the 
patient. Defervescence occurred within the ensuing five days. 
Approximately one month later a new ultrasound of the spleen 
showed a decrease of 1 cm in the diameter of all hypoechoic 
lesions (Fig. 2).
D I S C U S S I O N
Isolated involvement of the spleen is an extremely rare 
form of extrapulmonary tuberculosis. Most cases of tuber-
culous splenic involvement occur in the setting of milliary 
tuberculosis, during which bacilli are transferred hema-
togenously to the organ in 80-100% of cases.8 The typical 
milliary lesions may appear as tiny, round, low attenuation 
foci scattered throughout the organ.8 In the case of the rare 
isolated splenic tuberculosis, on the other hand, there is no 
involvement of other sites. It appears either as multiple, low 
attenuation, nodular lesions, or as an isolated low attenua-
tion mass or cavity, within an enlarged spleen.8 Differential 
diagnosis includes pyogenic abscess, fungal and parasitic 
infections, splenic infarct, metastatic cancer and primary 
neoplasm of the spleen.
Diagnosis frequently proves difficult, or even impossible, 
without the resection of the spleen. In our case, the recent 
initiation of treatment with an anti-TNF agent and the strongly 
positive TST, combined with the repeatedly negative blood 
cultures, raised the suspicion of extrapulmonary reactivation 
FIgURe 1. Computed tomography of the abdomen demon-
strating several discrete low attenuation foci within the mildly 
enlarged spleen. Liver and other internal organs were free of 
findings and no enlarged lymph nodes were noted.
FIgURe 2. ultrasound of the spleen performed five months 
later showing complete absence of the hypoechoic lesions in the 
spleen.
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of LTBI in the spleen. Isolated splenic tuberculosis is more 
common among immunosuppressed patients.9 Such cases have 
been sporadically reported in patients on infliximab,10,11 but 
this is the first time isolated splenic tuberculosis is described 
in association with adalimumab treatment. Of note is that in 
our patient all markers of inflammation were unaltered.
Similar to what has been observed with infliximab and 
etanercept,12 the majority of adalimumab-associated tuber-
culosis, some 62% of cases, represent extrapulmonary and/or 
disseminated disease.13 This trend coincides with the pattern 
of an underlying mechanism of immunosuppression that leads 
to reactivation of secondary foci and dissemination of myco-
bacteria. This is not surprising since the molecular integrity 
of TNFα is critical for the expression of adhesion molecules 
and chemotactic factors,14-16 the production of nitrogen reactive 
intermediates by the activated macrophages,17 the apoptosis 
of infected macrophages18 and, in overall, the timely accu-
mulation of monocytes and T cells and the development of 
structurally stable and functional granulomas, which engulf 
and neutralize the infectious foci.19 The monoclonal anti-TNF 
antibodies infliximab and adalimumab form stable, high affin-
ity complexes with all forms of TNFα, including the transmem-
brane form on the surface of macrophages and T cells.20 This 
latter action induces macrophage and T cell apoptosis.21,22 In 
addition, both infliximab and adalimumab appear to inhibit 
the activation of T cells, as well as the production of IFNγ, a 
cytokine that plays a major role in the host defense against my-
cobacterium tuberculosis.23-25 Thus, the multifactorial action 
of the monoclonal antibodies on the defensive type 1 helper 
T (Th1) cell response disturbs the structural and functional 
integrity of granulomas and increases the risk of reactivation 
of the secondary foci and spread of the bacilli.
Therefore current recommendations emphasize detection 
and treatment of LTBI prior to commencement of anti-TNF 
therapy. Although there are no standard guidelines, there is a 
general agreement that stringent pre-treatment management 
plays a major role in the prevention of anti-TNF associated 
tuberculosis. On the other hand, patients who are about to 
receive anti-TNF therapy are probably already immuno-
suppressed and may give misleading TST results. Thus, in 
patients with rheumatoid arthritis, screening sensitivity may 
be increased, at the cost of specificity, by lowering the TST 
threshold to 5 mm and give a booster dose 7-10 days after an 
initially negative test.26 The QuantiFERON-TB Gold (QFT-
G) test provides a more specific immunodiagnostic tool since 
it is not influenced by prior BCG vaccination or exposure 
to most atypical mycobacteria5 and the implementation of 
both methods in parallel has been expected to enhance both 
sensitivity and specificity of the screening.4,26 Furthermore, 
the tests may be repeated during anti-TNF therapy in order 
to detect possible conversions.27
Our patient, excluding his psoriasis, was an otherwise 
healthy individual with no predisposing factors for M. tubercu-
losis acquisition or reactivation. TST responses of 15 mm have 
specificity for LTBI exceeding 97%,6 but indurations less than 
10 mm are controversial, since other factors such as previous 
BCG vaccination or past exposure to atypical environmental 
mycobacteria may influence the result. In our case, the 8 mm 
induration of the screening TST was possibly considered to 
be due to a prior BCG vaccination during military service, 
a common practice in this country. This consideration was 
apparently further augmented by the negative QFT-G. How-
ever, although QFT-G demonstrates high specificity for M. 
tuberculosis infection, it is still questionable whether QFT-G 
sensitivity for LTBI is superior to that of TST.5 Moreover, 
since no gold standard exists for the diagnosis of LTBI, as-
sessing the sensitivity of QFT has limitations. In two recent 
studies from tuberculosis-low endemic countries, less than 
50% of individuals with TST responses of 15 mm or greater 
had positive QFT-G results.6,28 In one of them, TST-positive 
individuals were confirmed to be previously unvaccinated.6 
Such evidence suggests that QFT-G may actually miss a sub-
stantial number of LTBI cases. Finally, a recent meta-analysis 
showed that QFT-G has excellent specificity for LTBI, that 
is 99% for unvaccinated and 96% for vaccinated subjects, 
but its sensitivity is still considered rather suboptimal, being 
70-78%.29
C O N C l U S I O N
In conclusion, the already problematic LTBI screening 
may be further complicated by a history of prior BCG vaccina-
tion during adulthood in otherwise healthy individuals who 
are about to receive biologic agents. Our case demonstrates 
that even otherwise healthy individuals with no predisposing 
factors should be cautiously managed and perhaps TST cut-off 
values should be lower than the traditionally proposed in the 
face of biologic treatment. Further investigation is warranted 
for the incorporation of IGRAs in the initial evaluation. A 
lower cut-off value for QFT-G,6 or a prolonged 7-day assay,7 
may improve the performance of IGRAs and provide a more 
accurate evaluation of the IFN-γ response in such patients who 
are screened for LTBI. With regards to our patient, a booster 
TST after 7-10 days, and perhaps serial QFT-G testing dur-
ing anti-TNF therapy, could have possibly been a reasonable 
initial approach.
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